Literature DB >> 6106095

Intrathecal human tetanus immunoglobulin in early tetanus.

P S Gupta, R Kapoor, S Goyal, V K Batra, B K Jain.   

Abstract

97 patients with symptoms of early tetanus at the time of admission to hospital were treated with sedation, antibiotics, and human tetanus immune globulin (TIG). After intrathecal TIG 250 IU 3 patients out of 49 got worse but only 1 died while in a closely similar group of 48 patients in whom TIG was administered intramuscularly in dose of 1000 IU, the clinical features of the disease became severer in 15 (31%) and 10 (21%) died. The intrathecal use of TIG was devoid of side effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106095     DOI: 10.1016/s0140-6736(80)91883-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Human versus equine intramuscular antitoxin, with or without human intrathecal antitoxin, for the treatment of adults with tetanus: a 2 × 2 factorial randomised controlled trial.

Authors:  Nguyen Van Hao; Huynh Thi Loan; Lam Minh Yen; Evelyne Kestelyn; Duc Du Hong; Duong Bich Thuy; Nguyen Thanh Nguyen; Ha Thi Hai Duong; Tran Thi Diem Thuy; Phung Tran Huy Nhat; Phan Nguyen Quoc Khanh; Nguyen Thi Phuong Dung; Nguyen Hoan Phu; Nguyen Thanh Phong; Pham Thi Lieu; Pham Thi Tuyen; Bui Thi Bich Hanh; Ho Dang Trung Nghia; Pham Kieu Nguyet Oanh; Phan Vinh Tho; Tran Tan Thanh; Hugo C Turner; H Rogier van Doorn; Le Van Tan; Duncan Wyncoll; Nicholas Pj Day; Ronald B Geskus; Guy E Thwaites; Nguyen Van Vinh Chau; C Louise Thwaites
Journal:  Lancet Glob Health       Date:  2022-06       Impact factor: 38.927

3.  Elimination of maternal and neonatal tetanus: a 21st-century challenge.

Authors:  Sharon Owusu-Darko; Khady Diouf; Nawal M Nour
Journal:  Rev Obstet Gynecol       Date:  2012

4.  Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route.

Authors:  Demócrito de Barros Miranda-Filho; Ricardo Arraes de Alencar Ximenes; Antônio Alci Barone; Vicente Luiz Vaz; Aderbal Gomes Vieira; Valéria Maria Gonçalves Albuquerque
Journal:  BMJ       Date:  2004-03-05

5.  Failure of intrathecal antitetanus serum to improve survival in neonatal tetanus.

Authors:  J Neequaye; F K Nkrumah
Journal:  Arch Dis Child       Date:  1983-04       Impact factor: 3.791

6.  Intrathecal tetanus immunoglobulins in the management of tetanus.

Authors:  M G Geeta; P Krishnakumar; Lulu Mathews
Journal:  Indian J Pediatr       Date:  2007-01       Impact factor: 5.319

7.  Management of tetanus: a review of 18 cases.

Authors:  K O Sun; Y W Chan; R T Cheung; P C So; Y L Yu; P C Li
Journal:  J R Soc Med       Date:  1994-03       Impact factor: 18.000

8.  Generation of therapeutic antisera for emerging viral infections.

Authors:  Rebecca Schmidt; Lea C Beltzig; Bevan Sawatsky; Olga Dolnik; Erik Dietzel; Verena Krähling; Asisa Volz; Gerd Sutter; Stephan Becker; Veronika von Messling
Journal:  NPJ Vaccines       Date:  2018-10-05       Impact factor: 7.344

9.  Intrathecal Immunoglobulin for treatment of adult patients with tetanus: A randomized controlled 2x2 factorial trial.

Authors:  Huỳnh Thị Loan; Lam Minh Yen; Evelyne Kestelyn; Nguyen Van Hao; Tran Tan Thanh; Nguyen Thi Phuong Dung; Hugo C Turner; Ronald B Geskus; Marcel Wolbers; Le Van Tan; H Rogier Van Doorn; Nicholas P Day; Duncan Wyncoll; Tran Tinh Hien; Guy E Thwaites; Nguyen Van Vinh Chau; C Louise Thwaites
Journal:  Wellcome Open Res       Date:  2018-11-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.